Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.

Clin Epigenetics · 2015 · PMC4371799 · PMID 25806091

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP = 0.08so close (0.05 < p ≤ 0.1)

There was also a decrease in the mean nuclear CTR1 score from pre- to post-treatment; however, it did not reach statistical significance (67.5 vs. 42.5 (−25.0; 95% CI: −55.5, +5.5; P = 0.08)).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.